Jonathan Stamler, MD
Director, Harrington Discovery Institute, UH Cleveland Medical Center
Director, Institute for Transformative Molecular Medicine, UH Cleveland Medical Center
Professor, Medicine, CWRU School of Medicine
Director, Institute for Transformative Molecular Medicine, University Hospitals
President, Harrington Discovery Institute, University Hospitals
UH Cleveland Medical Center
Department of Medicine-Cardiovascular Medicine
11100 Euclid Ave
Case Western Reserve University - Wolstein Research Building
10900 Euclid Ave
LOC Code 7294
Pulmonary Hypertension, Vascular Disease, Cardiology, Coronary Artery Disease (CAD)
American Board of Internal Medicine - Internal Medicine
Education & Training
1985, Brandeis University
Medical / Professional School(s):
1985, Mount Sinai School of Medicine
1986, Internal Medicine - Brigham and Women's Hospital
1988, Internal Medicine - Brigham and Women's Hospital
1989, Pulmonary Disease - Brigham and Women's Hospital
1993, Cardiovascular Disease - Brigham and Women's Hospital
Patient Satisfaction Reviews
About Our Survey
At University Hospitals, we believe in providing patients with all the information they need to make educated decisions about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians. We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for every individual who sees a UH doctor.
There are no comments for this practitioner.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Jonathan Stamler, MD disclosed the following Outside Relationships with Industry:
SaberPharm - Intellectual Property